COVID passes, the headache stays

Gut zwei Jahre nach dem Ausbruch der Corona-Pandemie, die für eine lange Zeit die ganze Welt lahmlegen sollte, konnte endlich das Ende dieser Heimsuchung verkündet werden. Die Erleichterung auf dem gesamten Globus war groß. Das Virus war damit nicht aus der Welt. Aber es hatte nach Einschätzung von Expert:innen seinen pandemischen Schrecken verloren und war in einen endemischen Zustand übergegangen. Nun sollte die Zeit des Aufbruchs, des Wieder-Anknüpfens an das alte Leben beginnen.

Around two years after the outbreak of the coronavirus pandemic, which had the whole world paralysed for a long time, the end of this nightmare could finally be announced. The relief around the entire globe was great. Now, the time had come for a new start, for picking up the threads of life from beforehand. Sadly, this was not the case for everyone. For some of those infected with COVID, the virus had a more long-term impact, beyond the acute infection and sickness. The umbrella term ‘long COVID’ brings together a group of very different symptoms, which continue to burden affected people even after their apparent recovery.

What is long COVID?

The World Health Organisation (WHO) defines long COVID as symptoms which:

– generally begin around three months after becoming sick with COVID

– continue for at least two months and

– cannot be explained by another diagnosis.

As imprecise as this definition may be, this is how varied the manifestation of the illness is. For this reason, it also presents a particular challenge for the usual medical examination procedures. Affected people generally do not present with all the symptoms which are considered ‘typical’ for long COVID. Moreover, the symptoms are not permanent. They vary in severity and can even return after a symptom-free period. Most affected people are significantly impacted both in everyday life and in their overall wellbeing.

An unclear set of symptoms

Headaches, tiredness, shortness of breath, sleeping problems, joint and muscle pain, as well as anxiety and depression are among the frequently mentioned symptoms. In addition, there can be reductions in the ability to concentrate (also known as “brain fog”). There are also descriptions of changes to the senses of taste and smell – a phenomenon which is already familiar from acute COVID-19.

In terms of the frequency of the illness, the data from the available studies varies significantly. Depending on the study, the proportion of patients who initially became infected with COVID-19 is between 7 and around 40 percent, including both mild and severe courses, as well as hospitalisation.

A comprehensive evaluation of more than 30 studies showed, for example, that two months after the acute illness, the proportion of long COVID patients was around 17 percent, after six months this became 8 percent. According to an American study from 2023, 7 percent of convalescent patients showed signs of long COVID. One in four of those affected complained of limitations in everyday life.

Headache as a companion to viral illnesses – and also afterwards for COVID-19

The fact that headaches are one of the most common symptoms both in the context of an acute COVID-19 illness and for long COVID has been proven by numerous studies. This is unsurprising, as other viral infections can also often be accompanied by headaches. However, with long COVID, there is the additional risk that these pains can become chronic, or permanent. This impacts the affected people for a long time, even after the original viral infection has worn off.

The connection between long COVID and headaches can occur in different ways. For example, some people with migraine find that their existing illness worsens. After becoming infected with COVID, attacks occur more frequently or last longer than before.

For people who did not suffer from headaches prior to becoming ill with COVID-19, headaches can develop for the first time after the original infection has subsided. It seems that people with pre-existing symptoms are more likely to experience long-term difficulties due to headaches than people with no prior history with headaches.

A long COVID headache can manifest in affected people either as symptoms similar to migraine or as symptoms which are more consistent with tension headache.

How does a long COVID headache develop?

The emergence of the long COVID headache has been the subject of research since its discovery. For a long time, it was unclear what was causing the symptoms. It was speculated that the virus led to overall organ damage, that the immune system was affected, that viruses were persisting in the body, or that the prescribed medications had caused unwanted side effects.

A recently published paper from the USA (October 2023) could signal a breakthrough in the search for a cause. The researchers discovered that, during the acute illness with COVID-19, patients experienced a drop in serotonin circulating in the blood. Serotonin is a messenger substance in the human body. Its effects are highly varied. It affects the cardiovascular system, blood pressure and clotting, the gastrointestinal system, as well as pain perception and processing, to name only the most important ones.

In convalescent patients, serotonin levels returned to normal after they had overcome the viral infection. However, if the affected people developed long COVID, serotonin levels remained low. A similar lack of serotonin was also found in patients who had become infected with other viruses. Potentially, these findings have uncovered a general response to viral infections in the human body.

Immune response, serotonin, and headaches – a sensitive connection

When we come into contact with a virus, our innate immune system releases an increased number of so-called type I interferons. These immune messenger substances affect the intestinal mucosa, in which serotonin is formed. The interferons hinder the creation of serotonin in cells in the intestinal mucosa. A low serotonin level affects the coagulation activity of certain blood cells, the thrombocytes. This leads increasingly to the formation of microscopic, little clots in the blood vessels, which are frequently found in patients with long COVID. These can affect the blood supply.

The lack of serotonin also affects the function of the brain. While it cannot overcome the so-called blood-brain barrier, it is suspected that there is another mode of influence: if there is not enough serotonin available, the function of the so-called vagus nerve is affected. Among other things, this nerve is actively involved in controlling processes affecting memory, information storage, and also headache occurrences. This would explain the long COVID symptoms which lead to the typical dysfunctions – ‘brain fog’ – i.e., difficulty concentrating and fatigue, as well as headaches.

Vaccines are the key – even against long COVID

The good news: it is now well-substantiated that the COVID-19 vaccine can not only protect you from severe cases of the actual illness, but also significantly lowers the risk of long COVID. This means: the vaccine can also prevent secondary symptoms. A so-called booster vaccine, i.e., refreshing the protection given by the vaccination, is particularly effective here. For example, a study on healthcare workers was able to show an inverse relationship between the number of COVID-19 vaccinations and the risk of becoming sick with long COVID. According to the study, the likelihood of long COVID was reduced by two thirds after three vaccinations. We can therefore assume that the most effective preventative measure, not only against becoming ill through an infection with the virus, but also against long COVID, is the consistent use of the vaccine.

  • References
    • Azzolini E, Levi R, Sarti R, Pozzi C, Mollura M, Mantovani A, Rescigno M. Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers. JAMA. 2022 Aug 16;328(7):676-678. doi: 10.1001/jama.2022.11691. PMID: 35796131; PMCID: PMC9250078.
    • Bamps L, Armenti JP, Bojan M, Grandbastien B, von Garnier C, Du Pasquier R, Desgranges F, Papadimitriou-Olivgeris M, Alberio L, Preisig M, Schwitter J, Guery B, The RegCOVID Study Group. Long-Term Consequences of COVID-19: A 1-Year Analysis. J Clin Med. 2023 Apr 3;12(7):2673. doi: 10.3390/jcm12072673. PMID: 37048757; PMCID: PMC10095027.
    • Bowles S, Hickman J, Peng X, Williamson WR, Huang R, Washington K, Donegan D, Welle CG. Vagus nerve stimulation drives selective circuit modulation through cholinergic reinforcement. Neuron. 2022 Sep 7;110(17):2867-2885.e7. doi: 10.1016/j.neuron.2022.06.017. Epub 2022 Jul 19. PMID: 35858623; PMCID: PMC10212211.
    • Byambasuren O, Stehlik P, Clark J, Alcorn K, Glasziou P. Effect of covid-19 vaccination on long covid: systematic review. BMJ Med. 2023 Feb 1;2(1):e000385. doi: 10.1136/bmjmed-2022-000385. PMID: 36936268; PMCID: PMC9978692.
    • Chhabra N, Grill MF, Singh RBH. Post-COVID Headache: A Literature Review. Curr Pain Headache Rep. 2022 Nov;26(11):835-842. doi: 10.1007/s11916-022-01086-y. Epub 2022 Oct 5. PMID: 36197571; PMCID: PMC9533267.
    • Chippa V, Aleem A, Anjum F. Post-Acute Coronavirus (COVID-19) Syndrome. 2023 Feb 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 34033370.
    • Fujita K, Otsuka Y, Sunada N, Honda H, Tokumasu K, Nakano Y, Sakurada Y, Obika M, Hagiya H, Otsuka F. Manifestation of Headache Affecting Quality of Life in Long COVID Patients. J Clin Med. 2023 May 18;12(10):3533. doi: 10.3390/jcm12103533. PMID: 37240639; PMCID: PMC10219375.
    • Leng A, Shah M, Ahmad SA, Premraj L, Wildi K, Li Bassi G, Pardo CA, Choi A, Cho SM. Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics. Cells. 2023 Mar 6;12(5):816. doi: 10.3390/cells12050816. PMID: 36899952; PMCID: PMC10001044.
    • Lippi G, Sanchis-Gomar F, Henry BM. COVID-19 and its long-term sequelae: what do we know in 2023? Pol Arch Intern Med. 2023 Apr 19;133(4):16402. doi: 10.20452/pamw.16402. Epub 2023 Jan 9. PMID: 36626183.
    • Monje M, Iwasaki A. The neurobiology of long COVID. Neuron. 2022 Nov 2;110(21):3484-3496. doi: 10.1016/j.neuron.2022.10.006. Epub 2022 Oct 7. PMID: 36288726; PMCID: PMC9537254.
    • Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, Peligro PJ, Casimiro M, Guerrero JJ, Gellaco MML, Lippi G, Henry BM, Fernández-de-Las-Peñas C. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine. 2022 Aug 27;53:101624. doi: 10.1016/j.eclinm.2022.101624. PMID: 36051247; PMCID: PMC9417563.
    • Robertson MM, Qasmieh SA, Kulkarni SG, Teasdale CA, Jones HE, McNairy M, Borrell LN, Nash D. The Epidemiology of Long Coronavirus Disease in US Adults. Clin Infect Dis. 2023 May 3;76(9):1636-1645. doi: 10.1093/cid/ciac961. PMID: 36542514.
    • Rochmawati E, Iskandar AC, Kamilah F. Persistent symptoms among post-COVID-19 survivors: A systematic review and meta-analysis. J Clin Nurs. 2022 Nov 25. doi: 10.1111/jocn.16471. Epub ahead of print. PMID: 36426658.
    • Rodrigues AN, Dias ARN, Paranhos ACM, Silva CC, Bastos TDR, de Brito BB, da Silva NM, de Sousa EJS, Quaresma JAS, Falcão LFM. Headache in long COVID as disabling condition: A clinical approach. Front Neurol. 2023 Mar 23;14:1149294. doi: 10.3389/fneur.2023.1149294. PMID: 37034080; PMCID: PMC10076861.
    • Roever L, Cavalcante BRR, Improta-Caria AC. Long-term consequences of COVID-19 on mental health and the impact of a physically active lifestyle: a narrative review. Ann Gen Psychiatry. 2023 May 11;22(1):19. doi: 10.1186/s12991-023-00448-z. PMID: 37170283; PMCID: PMC10174610.
    • Szabo S, Zayachkivska O, Hussain A, Muller V. What is really 'Long COVID'? Inflammopharmacology. 2023 Apr;31(2):551-557. doi: 10.1007/s10787-023-01194-0. Epub 2023 Mar 25. PMID: 36964860; PMCID: PMC10039447.
    • Tana C, Bentivegna E, Cho SJ, Harriott AM, García-Azorín D, Labastida-Ramirez A, Ornello R, Raffaelli B, Beltrán ER, Ruscheweyh R, Martelletti P. Long COVID headache. J Headache Pain. 2022 Aug 1;23(1):93. doi: 10.1186/s10194-022-01450-8. PMID: 35915417; PMCID: PMC9340759.
    • Teodoro T, Chen J, Gelauff J, Edwards MJ. Functional neurological disorder in people with long COVID: A systematic review. Eur J Neurol. 2023 May;30(5):1505-1514. doi: 10.1111/ene.15721. Epub 2023 Feb 22. PMID: 36719069.
    • Wong AC, Devason AS, Umana IC, Cox TO, Dohnalová L, Litichevskiy L, Perla J, Lundgren P, Etwebi Z, Izzo LT, Kim J, Tetlak M, Descamps HC, Park SL, Wisser S, McKnight AD, Pardy RD, Kim J, Blank N, Patel S, Thum K, Mason S, Beltra JC, Michieletto MF, Ngiow SF, Miller BM, Liou MJ, Madhu B, Dmitrieva-Posocco O, Huber AS, Hewins P, Petucci C, Chu CP, Baraniecki-Zwil G, Giron LB, Baxter AE, Greenplate AR, Kearns C, Montone K, Litzky LA, Feldman M, Henao-Mejia J, Striepen B, Ramage H, Jurado KA, Wellen KE, O'Doherty U, Abdel-Mohsen M, Landay AL, Keshavarzian A, Henrich TJ, Deeks SG, Peluso MJ, Meyer NJ, Wherry EJ, Abramoff BA, Cherry S, Thaiss CA, Levy M. Serotonin reduction in post-acute sequelae of viral infection. Cell. 2023 Oct 9:S0092-8674(23)01034-6. doi: 10.1016/j.cell.2023.09.013. Epub ahead of print. PMID: 37848036.